Licence agreementGenethon licenses core AB-1009 technology to AskBio after IND clearanceFrench gene therapy research institute Genethon announced it has signed an exclusive global license with AskBio that allows the company to use Genethon-patented technology incorporated in AB-1009, an … more ➔
RegulatoryEMA and FDA join forces: Aligned principles on AI use in drug developmentThe European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have together compiled ten principles for good artificial intelligence (AI) practice in drug development. more ➔
FundingWith a €6.26M round, QLi5 doubles down on proteasome-based ADC payloadsQLi5 Therapeutics has completed a €6.26 million capital increase led by its Korean co-founder, Qurient, which has also increased its voting stake in the German biotech. The funding will be used to … more ➔
photo credit: BioInnovation Institute/Esben Zøllner OlesenInvestmentNovo Nordisk Foundation commits DKK 5.5 billion to scale European biotech innovationThe Novo Nordisk Foundation has committed up to DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII), a Copenhagen-based hub for life science and deep tech entrepreneurship. The long-term … more ➔
CDC.govHerpes VirusMunich’s Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviralMunich-based Innovative Molecules steps into the spotlight with a partnership with Italy’s Alfasigma. The deal brings fresh capital and a global licence for adibelivir, a next-generation antiviral … more ➔
TQ Therapeutics GmbHCell therapiesFaster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ TherapeuticsFresenius Kabi and TQ Therapeutics have entered into a strategic development agreement in cell and gene therapy. Fresenius Kabi receives an exclusive licence to develop, manufacture and distribute products … more ➔
BioNTech SEBioNTech2026: A year of reckoning for BioNTechFor BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook … more ➔
M&AEli Lilly-Abivax €15 billion takeover rumor stirs markets, but no formal steps confirmedWhile much of the biotech industry is focused on meetings and dealmaking at the J.P. Morgan (JPM) Healthcare Conference, a rumor has cut through the JPM noise. The possibility of Eli Lilly making a move … more ➔
Fundingbit.bio closes a $50 million series C round after its 2025 restructuringbit.bio has raised $50 million in a series C round led by M&G Investments to support the next phase of its human cell programming business. The Cambridge-based company develops defined human cells using … more ➔
RocheRocheSecond time around: Roche’s return to MediLink underlines the value of the first dealRoche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate … more ➔
photo credit: BioInnovation Institute/Esben Zøllner Olesen
CDC.gov
TQ Therapeutics GmbH
BioNTech SE
Roche